{"url_path":"/sec/slxnw/8-k/2026-05-13/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002624-index.html","accession_number":"0001178913-26-002624","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002624-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":147,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn May 13, 2026, Silexion Therapeutics\nCorp issued a press release entitled “Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading\nGlobal CDMO”. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Form 8-K”) and is incorporated herein by reference.\n\n \n\nThe information in this Item 7.01 of Form 8-K, including the information in the press release furnished pursuant to\nthis Item 7.01, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in this Item 7.01, including the\ninformation in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended."}